Biological and Pharmaceutical Bulletin · 2022 · 13 citations · 17 references
MedicinePharmacologyPharmacotherapyAutoimmunityMolecular PharmacologyRheumatologyAutoimmune Disease PathogenesisAutoimmune DiseasesAutoimmune InflammationAutoimmune Rheumatic DiseasesInflammatory ArthritisRheumatoid ArthritisCollagen-induced ArthritisInflammatory Cytokine EffectsInflammatory Cytokine ProductionInterleukin 17 InhibitionRheumatoid Arthritis ModelsRheumatoid Arthritis TherapyTh17 ResponsesTreatment Adverse Effects
Rheumatoid arthritis (RA) is systemic autoimmune arthritis that causes joint inflammation and destruction. Accumulating evidence has shown that inhibitors of class I histone deacetylases (HDACs) (i.e., HDAC1, 2, 3, and 8) are potential therapeutic candidates as targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs). Nevertheless, the inhibition of class I HDACs has severe adverse effects because of their broad spectrum. We evaluated the therapeutic effect of a novel selective HDAC1 inhibitor TTA03-107 for collagen-induced arthritis (CIA) and collagen antibody-induced arthritis (CAIA) models in mice. We also examined the effect of TTA03-107 in bone marrow-derived macrophages (BMDMs) and T helper 17 (Th17) cells in vitro. Here, we delineate that TTA03-107 reduced the severity of autoimmune arthritis without obvious adverse effects in CIA and CAIA models. Moreover, TTA03-107 suppressed the production of inflammatory cytokines, such as interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and IL-17A, in serum and joint tissue. In vitro treatment of BMDMs with TTA03-107 dampened the M1 differentiation and inflammatory cytokine production. TTA03-107 also suppressed the differentiation of Th17 cells. These results demonstrate that TTA03-107 can attenuate the development of arthritis in experimental RA models by inhibiting the differentiation and activation of macrophages and Th17 cells. Therefore, TTA03-107 is a potential tsDMARD candidate.
17
Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis
Noriko Komatsu, Kazuo Okamoto, Shinichiro Sawa et al. · Nature Medicine · 2013 · 1.1K citations
Life Sciences, Immunology, Pathology +17